HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.

Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease leading to axonal injury. Even if the etiology of MS is still unknown the disease begins with inflammation involving autoreactive T lymphocytes activation in genetically susceptible subjects. Interferon beta-1b (IFN β 1b) is one of the most used drug in the MS therapy. The results obtained in this study show that the concentration of SOD1 in CSF of relapsing-remitting MS (RR-MS) patients, evaluated by enzyme-linked immunosorbent assay (ELISA), is decreased compared to pathological controls. Moreover, the Western blotting analysis demonstrated that SOD1 in human peripheral blood mononuclear cells (PBMC) in healthy controls was significantly higher compared to MS subjects before starting DMT therapy. In addition IFN β 1b therapy causes an increase of intracellular SOD1 protein as well as mRNA levels in PBMC. Moreover, the treatment of neuroblastoma SK-N-BE cells with IFN β 1b increased SOD1 protein and mRNA levels; these data also suggest that neuroprotective effect of this physiological molecule is, at least in part, carried out through its effect on SOD1. This study demonstrate that DMT therapy is able to increase SOD1 expression in PBMC of RR-MS patients. Therefore, the effectiveness of DMT therapy can be ascribed, at least in part, to an increased levels of this antioxidant enzyme as further confirmed by in vitro studies in SK-N-BE cells.
AuthorsSimona Damiano, Anna Sasso, Bruna De Felice, Giuseppe Terrazzano, Vincenzo Bresciamorra, Antonio Carotenuto, Nicola S Orefice, Giuseppe Orefice, Giovanni Vacca, Annamaria Belfiore, Mariarosaria Santillo, Paolo Mondola
JournalBrain research bulletin (Brain Res Bull) Vol. 118 Pg. 1-6 (Sep 2015) ISSN: 1873-2747 [Electronic] United States
PMID26327496 (Publication Type: Clinical Trial, Journal Article)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • RNA, Messenger
  • SOD1 protein, human
  • Interferon beta-1b
  • Superoxide Dismutase
  • Superoxide Dismutase-1
Topics
  • Adult
  • Blotting, Western
  • Case-Control Studies
  • Cell Line, Tumor
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Interferon beta-1b (therapeutic use)
  • Leukocytes, Mononuclear (drug effects, enzymology)
  • Male
  • Multiple Sclerosis, Relapsing-Remitting (blood, drug therapy, enzymology)
  • Neuroblastoma (drug therapy, enzymology)
  • RNA, Messenger (blood)
  • Superoxide Dismutase (blood, metabolism)
  • Superoxide Dismutase-1

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: